"1212-7973" . . . "27" . "RIV/00098892:_____/13:#0000636" . "2" . . "Urb\u00E1nek, Jaroslav" . . "Cetuximab je monoklon\u00E1ln\u00ED protil\u00E1tka proti receptoru epiderm\u00E1ln\u00EDho r\u016Fstov\u00E9ho faktoru (EGFR), kter\u00E1 se \u00FA\u010Dinn\u011B vyu\u017E\u00EDv\u00E1 p\u0159i l\u00E9\u010Db\u011B r\u016Fzn\u00FDch typ\u016F onkologick\u00FDch onemocn\u011Bn\u00ED. U\u017Eit\u00ED t\u00E9to protin\u00E1dorov\u00E9 terapie je velmi \u010Dasto spojeno s projevy ko\u017En\u00ED toxicity, kter\u00E1 je zp\u016Fsoben\u00E1 vazbou cetuximabu na EGFR v k\u016F\u017Ei. Tento ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F zhor\u0161uje kvalitu \u017Eivota onkologick\u00FDch pacient\u016F a v p\u0159\u00EDpadech t\u011B\u017Ek\u00FDch toxick\u00FDch reakc\u00ED vy\u017Eaduje sn\u00ED\u017Een\u00ED d\u00E1vky nebo v\u00FDjime\u010Dn\u011B i p\u0159eru\u0161en\u00ED l\u00E9\u010Dby inhibitory EGFR. Auto\u0159i popisuj\u00ED p\u0159\u00EDpad 50let\u00E9 \u017Eeny l\u00E9\u010Den\u00E9 pro pokro\u010Dil\u00FD karcinom orofaryngu s \u0161\u00ED\u0159en\u00EDm do hypofaryngu prov\u00E1zen\u00FD akneiformn\u00ED erupc\u00ED, kter\u00E1 je nej\u010Dast\u011Bj\u0161\u00EDm projevem ko\u017En\u00ED toxicity u t\u00E9to protin\u00E1dorov\u00E9 l\u00E9\u010Dby." . "Cetuximab je monoklon\u00E1ln\u00ED protil\u00E1tka proti receptoru epiderm\u00E1ln\u00EDho r\u016Fstov\u00E9ho faktoru (EGFR), kter\u00E1 se \u00FA\u010Dinn\u011B vyu\u017E\u00EDv\u00E1 p\u0159i l\u00E9\u010Db\u011B r\u016Fzn\u00FDch typ\u016F onkologick\u00FDch onemocn\u011Bn\u00ED. U\u017Eit\u00ED t\u00E9to protin\u00E1dorov\u00E9 terapie je velmi \u010Dasto spojeno s projevy ko\u017En\u00ED toxicity, kter\u00E1 je zp\u016Fsoben\u00E1 vazbou cetuximabu na EGFR v k\u016F\u017Ei. Tento ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F zhor\u0161uje kvalitu \u017Eivota onkologick\u00FDch pacient\u016F a v p\u0159\u00EDpadech t\u011B\u017Ek\u00FDch toxick\u00FDch reakc\u00ED vy\u017Eaduje sn\u00ED\u017Een\u00ED d\u00E1vky nebo v\u00FDjime\u010Dn\u011B i p\u0159eru\u0161en\u00ED l\u00E9\u010Dby inhibitory EGFR. Auto\u0159i popisuj\u00ED p\u0159\u00EDpad 50let\u00E9 \u017Eeny l\u00E9\u010Den\u00E9 pro pokro\u010Dil\u00FD karcinom orofaryngu s \u0161\u00ED\u0159en\u00EDm do hypofaryngu prov\u00E1zen\u00FD akneiformn\u00ED erupc\u00ED, kter\u00E1 je nej\u010Dast\u011Bj\u0161\u00EDm projevem ko\u017En\u00ED toxicity u t\u00E9to protin\u00E1dorov\u00E9 l\u00E9\u010Dby."@cs . "Klinick\u00E1 farmakologie a farmacie" . "[2C6ACF7E273F]" . "The monoclonal antibody cetuximab, an inhibitor of epidermal growth factor receptor (EGFR), has been effectively used to treat various types of cancer. However, these agents frequently cause skin toxicity, which is due to the expression of the EGFR in the skin. This adverse effect impairs the quality of life of cancer patients and, in severe cases, requires dose reduction, or rarely, even discontinuation of treatment. Therefore, timely initiation of anticancer therapy is important."@en . "3"^^ . "95248" . "Papulopustular exanthema as an adverse effect of cetuximab"@en . . . . . "Papulopustul\u00F3zn\u00ED exant\u00E9m jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek cetuximabu"@cs . "Papulopustul\u00F3zn\u00ED exant\u00E9m jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek cetuximabu" . . . "I, V" . "RIV/00098892:_____/13:#0000636!RIV14-MZ0-00098892" . . . "Papulopustul\u00F3zn\u00ED exant\u00E9m jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek cetuximabu" . "2"^^ . . . "Papulopustular exanthema as an adverse effect of cetuximab"@en . "1"^^ . "adverse effects, cetuximab"@en . . "CZ - \u010Cesk\u00E1 republika" . "Papulopustul\u00F3zn\u00ED exant\u00E9m jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek cetuximabu"@cs .